BioMed Central Blog

NIH Public Access Policy to become mandatory
Many open access advocates will already have heard that NIH's Public Access Policy, until now voluntary, is set to become mandatory following President Bush's approval on Dec 26th 2007 of the latest NIH appropriations bill, which includes the following wording:
"The Director of the National Institutes of Health shall require that all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication to be made publicly available no later than 12 months after the official date of publication: Provided, That the NIH shall implement the public access policy in a manner consistent with copyright law."
This is great news both for researchers and for the general public. Peter Suber's January SPARC Open Access Newsletter contains a detailed analysis of what the change means, and identifies some of the key issues that remain to be resolved.
Perhaps predictably, the publishing organizations who had lobbied strenuously but unsuccessfully against the new policy have lost no time in issuing statements condemning it and forecasting dire consequences. Statements from the Association of American Publishers and STM appear to take the curious position that it is the publishing organizations who are the rightful owners of the intellectual results of scientific research, and that the NIH is taking an appalling liberty by asserting, on behalf of the public, any rights at all over these results.
According to the AAP:
"[C]hanging to a new mandatory policy that will ‘require’ such submission eliminates the concept of permission, and effectively allows the agency to take important publisher property interests without compensation, including the value added to the article by the publishers’ investments in the peer review process and other quality-assurance aspects of journal publication. It undermines publishers’ ability to exercise their copyrights in the published articles, which is the means by which they support their investments in such value-adding operations"
According to STM, meanwhile:
"The legislation neither provides compensation for the added-value of services that these manuscripts have received from publishers nor does it earmark funds to ensure the economic sustainability of the broad and systematic archiving this sort of project requires. It also undermines a key intellectual property right known as copyright - long a cornerstone used to foster creativity and innovation."
Mind boggling stuff...The first point to make, in response, is to note the matter of
timing. A potential author signs an agreement with NIH concerning the
conditions of their grant funding long before any manuscript resulting from
that funding is submitted to a publisher. If a publisher does not like the NIH
policy, they are within their rights to choose not to consider submissions from
NIH-funded authors. But a publisher cannot reasonably claim that NIH is appropriating
its intellectual property, since the author's pre-existing contractual
agreement, at the point of manuscript
submission, is entirely with NIH, not with the publisher. The publisher has no claim whatsoever over the research at that point.
Secondly, copyright, far from being threatened by open access, is the essential legal framework that makes open access possible. The Creative Commons open access license, under which all BioMed Central research articles are distributed, depends entirely on copyright for its legal validity. Traditional publishers may not like an arrangement in which they are no longer the exclusive copyright owners, but that hardly means that such a situation 'undermines' copyright.
Thirdly, and finally: in financial terms the investment made by a publisher in managing the peer-review and publication process for a typical biomedical research publication amounts to roughly 1% of what was invested by the funder in carrying out the research. (i.e. a few thousand dollars of input by the publisher, compared to a few hundred thousand dollars spent by the funder). In such circumstances, it is quite something for the publishers to claim that they are hard done by if they do not receive exclusive rights to the resulting research article in return for their efforts...
In the context of the publication of original scientific and medical research articles, publishers are not the content creators, nor should they be the content owners. Publishers are service providers, and should compete to provide the best service to the scientific community on that basis. 180+ open access journals from BioMed Central and around 3000 more listed in the Directory of Open Access Journals demonstrate the appeal and viability of this approach.
[Peter Suber has posted detailed rebuttals of the AAP and STM statements, here and here respectively.]
Update: 14th Jan 2008
The NIH has released the text of its new policy, and has also created an accompanying Public Access FAQ.
Posted by Matthew Cockerill at 19:52 Comments (11)




Thank you, thank you, thank you.
Posted by Nicole Bernshaw on January 16, 2008 at 04:19 AM GMT #
Intellectual rights of an article or report belong to the person or entity that originated the research, and/or conducted the analysis of the data and/or produced information. I.e. to those who made a major intellectual contribution in the process.
Research funded by private agent as part of its R&D may or may not be published as an article (differentiate this from management of information of public interest and/or from the utilization of the information they produce).
The publishers, generalizations allowed, do not originate research, fund it, conduct it, nor produce information based on data obtained. What they basically own is the format, unless the authors concede their intellectual right.
It is clear that peer reviewed, high quality, open access publishing is possible. If some publishers can not adapt to current times, it is their fault.
Posted by Jaime Chang on January 16, 2008 at 01:30 PM GMT #
Posted by Angela Masterson on January 16, 2008 at 01:45 PM GMT #
Posted by 165.91.28.90 on January 16, 2008 at 02:46 PM GMT #
As scientists we are interested in protocol details sufficient to replicate study--and the raw data by subject and occasion of measurement sufficient to reanalyse data.
the current data summaries are constricted by historical paper journals--but not by the internet. combined with registries the current problem in product evaluation--acutely-would be fixed.
the problem with postmarketing surveillance for safety,efficacy across non FDA treatments-eg surgery,psychotherapy,nutraceuticals--takes an entirel different level of integrated computerized cross-linked medical , lab,coroner etc public,records.
Posted by donald klein md on January 16, 2008 at 03:42 PM GMT #
Don Klein
Posted by donald klein md on January 16, 2008 at 03:46 PM GMT #
Lynn Howard Ehrle, M. Ed., Senior Biomedical Policy Analyst (pro bono),
Organic Consumers Association (OCA) and Chair of its special project, the International Science Oversight Board
Posted by Lynn Howard Ehrle on January 16, 2008 at 04:18 PM GMT #
Posted by John Veranth on January 16, 2008 at 05:44 PM GMT #
Not entirely accurate. All that the publishers are claiming is the right to copyright, which each and every author of a scientific paper for the journals in question willingly signed away.
Posted by Rich Apodaca on January 17, 2008 at 04:56 PM GMT #
Posted by Sven Hovmöller on January 17, 2008 at 07:13 PM GMT #
Printing on paper is very expensive. The publishers' complaints remind me of what has been going on in the music industry regarding downloadable music, the film and television production industry regarding the writers' strike, newspaper publishers competing with online sources of news, and so on. At any rate, the journal publishers will have to accept the new realities of today's world.
Posted by John A. Mozzer on January 22, 2008 at 06:51 AM GMT #